LivaNova PLC (LIVN)
- Previous Close
43.55 - Open
43.57 - Bid 31.14 x 200
- Ask 55.41 x 200
- Day's Range
43.08 - 43.60 - 52 Week Range
32.48 - 63.57 - Volume
168,226 - Avg. Volume
895,155 - Market Cap (intraday)
2.359B - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
-- - EPS (TTM)
-4.07 - Earnings Date Jul 29, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
61.50
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
www.livanova.comRecent News: LIVN
View More
Performance Overview: LIVN
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LIVN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LIVN
View MoreValuation Measures
Market Cap
2.37B
Enterprise Value
2.31B
Trailing P/E
--
Forward P/E
21.88
PEG Ratio (5yr expected)
1.95
Price/Sales (ttm)
1.87
Price/Book (mrq)
2.30
Enterprise Value/Revenue
1.81
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-17.42%
Return on Assets (ttm)
4.55%
Return on Equity (ttm)
-19.70%
Revenue (ttm)
1.28B
Net Income Avi to Common (ttm)
-222.14M
Diluted EPS (ttm)
-4.07
Balance Sheet and Cash Flow
Total Cash (mrq)
738.44M
Total Debt/Equity (mrq)
65.54%
Levered Free Cash Flow (ttm)
782.12M
Research Analysis: LIVN
View MoreResearch Reports: LIVN
View MoreRating decreased to a HOLD
LIVANOVA PLC has an Investment Rating of HOLD; a target price of $46.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetLivanova Earnings: Robust First-Quarter Results Kick Off Strong Start to Year
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
RatingPrice TargetLowering target price to $39.00
LIVANOVA PLC has an Investment Rating of BUY; a target price of $39.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRaising target price to $41.00
LIVANOVA PLC has an Investment Rating of BUY; a target price of $41.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target